Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Lymphoma: early-phase trial registry
88 of 330 indexed Lymphoma trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #21 of 28,707 conditions by registered trial count.
330 US clinical trials · 88 currently recruiting · #21 of 28,707 conditions by registered trial count
Lymphoma: 330 US clinical trials tracked, 88 recruiting.
Lymphoma is the subject of 330 registered US clinical trials on ClinicalTrials.gov, 88 of them currently open to new participants. 25 are in Phase 3-4 (later-stage) and 229 in Phase 1-2 (earlier-stage). The most active sponsor is Memorial Sloan Kettering Cancer Center, running 34 of these trials.
Enrollment posture brief
Registry condition lymphoma
OPEN 88 | RECR 27% | LATE 25 | EARLY 229 | RANK #21 | SPON 34
Volume-matched condition peers
Nearest open-share peer: Age-related Macular Degeneration (27% recruiting · 75 trials)
Lymphoma lists 88 open slots (27% of 330 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Lymphoma on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Lymphoma is recruiting below its size-band peers.
88 of 330 indexed trials (26.7%) are open to enrollment, against a 37.1% average across 139 conditions with 100+ trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Lymphoma trials is spread across many organizations.
Memorial Sloan Kettering Cancer Center accounts for 34 of 330 trials (10.3%). 116 distinct sponsors appear on at least one study for this condition label.
-
Most Lymphoma trials plan to enrol fewer than 100 people.
Median target enrolment is 50 among the 300 trials that report a genuine target (sentinel values excluded). 213 of those (71%) plan for fewer than 100 participants.
-
Lymphoma research is mostly interventional.
299 interventional and 31 observational studies make up this index (90.6% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
330 total, page 4 of 7
Flu Vaccine in Preventing Influenza Infection in Healthy Volunteers and in Patients Who Have Undergone Stem Cell Transplant
City of Hope Medical Center
NCT00964821
Combination Chemotx in Treating Children or Adolescents With Newly Diagnosed Stg III or Stg IV Lymphoblastic Lymphoma
Children's Oncology Group
NCT00004228
Combination Chemotherapy and Donor Stem Cell Transplant in Treating Patients With Aplastic Anemia or Hematologic Cancer
Roswell Park Cancer Institute
NCT00003816
A Study of Polatuzumab Vedotin (DCDS4501A) in Combination With Rituximab or Obinutuzumab Plus Bendamustine in Participants With Relapsed or Refractory Follicular or Diffuse Large B-Cell Lymphoma
Hoffmann-La Roche
NCT02257567
Chemotherapy Followed by Radiation Therapy in Treating Young Patients With Newly Diagnosed Hodgkin's Disease
Children's Oncology Group
NCT00002827
Illness Management and Parental Adjustment to Cancer Treatment
Children's Hospital Medical Center, Cincinnati
NCT02505165
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Mayo Clinic
NCT00436618
Epoetin Alfa in Treating Anemia in Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Multiple Myeloma and Anemia Caused By Chemotherapy
Memorial Sloan Kettering Cancer Center
NCT00003341
Study of CC-122 to Evaluate the Safety, Tolerability, and Effectiveness for Patients With Advanced Solid Tumors, Non-Hodgkin's Lymphoma, or Multiple Myeloma
Celgene
NCT01421524
Glutamic Acid in Reducing Nerve Damage Caused by Vincristine in Young Patients With Cancer
University of South Florida
NCT00369564
The In4M Study: Integrating 4 Methods to Assess Physical Function in Cancer Patients
Yale University
NCT05214144
PK-directed Dose Adjustment of IV Busulfan Conditioning Regimen for Autologous Stem Cell Transplant in Lymphoma Patients
Otsuka Pharmaceutical Development & Commercialization
NCT00948090
A Web-Based Stem Cell Transplant Support System or Standard Care in Young Patients Undergoing Stem Cell Transplant and Their Families
Tufts Medical Center
NCT00782145
Phase 1b/2 Study of Carfilzomib in Relapsed Solid Tumors, Multiple Myeloma, or Lymphoma
Amgen
NCT00531284
Allo Non-Myeloablative SCT Utilizing Mis-Matched Family Member Stem Cells Purged Using Campath
David Rizzieri, MD
NCT00580034
A Study of Investigational SAR245409 in Patients With Certain Lymphoma or Leukemia
Sanofi
NCT01403636
Chemotherapy Based on Positron Emission Tomography Scan in Treating Patients With Stage I or Stage II Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT01132807
Peripheral Stem Cell Transplantation in Treating Patients With Non-Hodgkin's Lymphoma or Hodgkin's Disease
H. Lee Moffitt Cancer Center and Research Institute
NCT00005613
Gemcitabine and Hodgkin's Disease Chemotherapy Followed by Peripheral Blood Stem Cell Rescue for Hodgkin's Disease
Stanford University
NCT00388349
Effect of Zoledronic Acid on Chemotherapy Induced Bone Loss
M.D. Anderson Cancer Center
NCT00352846
Two Different Methods of Collecting Stem Cells For an Autologous Stem Cell Transplant in Treating Patients With Diffuse Large Cell Lymphoma
Mayo Clinic
NCT00566228
Collect and Assess Tissue Samples From Subjects With Hematologic Malignancy
Notable Labs
NCT04014764
Monoclonal Antibody Therapy and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT00301821
Rituximab, Chemotherapy, and Filgrastim in Treating Patients With Burkitt's Lymphoma or Burkitt's Leukemia
Alliance for Clinical Trials in Oncology
NCT00039130
Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage I or Stage II Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
NCT00086801
Response-Based Therapy Assessed By PET Scan in Treating Patients With Bulky Stage I and Stage II Classical Hodgkin Lymphoma
Alliance for Clinical Trials in Oncology
NCT01118026
Nutrition and Physical Activity Intervention in Preventing Excess Weight Gain in Pediatric Patients With Leukemia or Lymphoma Treated With Prednisone and/or Dexamethasone
M.D. Anderson Cancer Center
NCT05049785
Clinical Evaluations and Laboratory Studies to Study the Disease Course in Patients With Cutaneous T-Cell Lymphoma
National Institutes of Health Clinical Center (CC)
NCT00430053
Rituximab and Combination Chemotherapy in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-Cell Non-Hodgkin's Lymphoma
Eastern Cooperative Oncology Group
NCT00274924
Chemotherapy and Rituximab With or Without Total-Body Irradiation and Peripheral Stem Cell Transplant in Treating Patients With Lymphoma
Memorial Sloan Kettering Cancer Center
NCT00039195
Opioid Titration Order Sheet or Standard Care in Treating Patients With Cancer Pain
Vanderbilt-Ingram Cancer Center
NCT00666211
A Safety and Pharmacology Study of Atezolizumab (MPDL3280A) Administered With Obinutuzumab or Tazemetostat in Participants With Relapsed/Refractory Follicular Lymphoma and Diffuse Large B-cell Lymphoma
Hoffmann-La Roche
NCT02220842
Rituximab, Cyclophosphamide, and Pegfilgrastim in Treating Patients With Leukemia or Non-Hodgkin's Lymphoma
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
NCT00278161
Combination Chemotherapy in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
NCT00006029
African American Cancer Clinical Trial Decisions: Testing Tailored Messages
Virginia Commonwealth University
NCT02356549
Sym021 Monotherapy, in Combination With Sym022 or Sym023, and in Combination With Both Sym022 and Sym023 in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Symphogen A/S
NCT03311412
Monoclonal Antibody Therapy in Treating Patients With Lymphoma or Colon Cancer That Has Not Responded to Vaccine Therapy
National Institutes of Health Clinical Center (CC)
NCT00047164
Cord Blood With T-Cell Depleted Haplo-identical Peripheral Blood Stem Cell Transplantation for Hematological Malignancies
Memorial Sloan Kettering Cancer Center
NCT01682226
Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma
Alliance for Clinical Trials in Oncology
NCT00062114
Combination Chemotherapy in Treating Patients With Non-Hodgkin's Lymphoma or Acute Lymphocytic Leukemia
Children's Oncology Group
NCT00005977
Donor Stem Cell Transplant in Treating Patients With Relapsed Hematologic Cancer
Alliance for Clinical Trials in Oncology
NCT00053196
A Phase I Study of Infusional Chemotherapy With the P-Glycoprotein Antagonist PSC 833
National Cancer Institute (NCI)
NCT00001302
Improving Patient Education for Lymphoma and Leukemia Inpatients
Emory University
NCT02642510
Vorinostat With Gemcitabine, Busulfan, and Melphalan With Stem Cell Transplant (SCT) in Relapsed or Refractory Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT01421173
DNA Analysis in Predicting Response to Antibody Therapy in Patients With Follicular Lymphoma Treated on Clinical Trials CALGB-50402 or CALGB-50701
Alliance for Clinical Trials in Oncology
NCT01057459
Amifostine for Head and Neck Irradiation in Lymphoma
Dana-Farber Cancer Institute
NCT00136474
The Collection of Peripheral Blood Lymphocytes and Marrow Progenitor Cells From Normal Volunteers and Volunteers With Lymphoid or Hematologic Malignancies
National Cancer Institute (NCI)
NCT00001432
Rituximab, Cladribine, and Temsirolimus in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma
Alliance for Clinical Trials in Oncology
NCT00787969
Donor Umbilical Cord Blood Transplant in Treating Patients With Hematologic Cancer
Fred Hutchinson Cancer Center
NCT00723099
Safety and Efficacy of 90Y Zevalin in Nonmyeloablative Transplantation for Lymphoid Malignancies
M.D. Anderson Cancer Center
NCT00048737
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 119 |
| Phase 2 | 110 |
| Phase 3 | 22 |
| Phase 4 | 3 |
Top Sponsors
Named interventions
Most-linked intervention names on Lymphoma records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Lymphoma trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Lymphoma page
330 registered trials, 88 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 88 Lymphoma trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Memorial Sloan Kettering Cancer Center sponsors the most Lymphoma trials on record, review their full trial history before evaluating a specific study. See Memorial Sloan Kettering Cancer Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Lymphoma condition card totals 330 registered trials; most-linked intervention cyclophosphamide; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.